Adequate control of blood pressure (BP) is important to slow the progression of chronic renal failure (CRF). The Joint National Committee (JNC) VI recommends BP o130/85 mmHg, or o125/75 mmHg if urinary protein excretion exceeds 1 g/d. Angiotensin converting enzyme inhibitors (ACE-I) are considered as first-line agents. The current study is a survey of the degree of goal achievement and prescription patterns of antihypertensive (AHT) medication according to the JNC guidelines in clinical nephrology practice. All patients with CRF, not on renal replacement therapy, treated by nephrologists at the University Hospital of North-Norway were included in this retrospective cross-sectional study. Data on protein:creatinine ratio (PC ratio), BP and AHT drugs prescribed were extracted from the hospital's databases and medical records. A total of 144 patients were included. The patients' age was 62716 years and the serum creatinine value was 210792 lmol/l (mean7s.d.). In all, 74 patients (51%) had PC ratio p1, 36 (25%) 41, and for 34 (24%) PC ratio had not been measured; 23 (31%) of the patients with PC ratio p1 had BP p130/85 (139721/78712), and 5 (14%) of those with PC ratio 41 had BP p125/75 (145722/85714). Failure to achieve the goal was most commonly due to elevated SBP. In all, 55 % of the patients were prescribed ACE-I or angiotensin receptor blocker (ARB). In conclusion, the recommended BP goals may be difficult to achieve for a high proportion of patients in clinical practice due to difficulty in lowering SBP. There is a potential for improved treatment of hypertension in CRF patients, including increased prescription of ACE-I and ARB.
Introduction
Chronic renal failure (CRF) is usually a progressive disease, but the mechanisms underlying its progression vary and are not completely understood. 1 However, hypertension is recognised as one of the main contributing factors, and it has been convincingly demonstrated that lowering of blood pressure (BP) below what is recommended for patients with essential hypertension slows the progression. In the Modification of Diet in Renal Disease (MDRD) study, the mean decline in glomerular filtration rate (GFR) over 3 years was 11.877.3 ml/min slower in patients randomised to low BP compared with usual BP. The greatest beneficial effect was seen in patients with high urinary protein excretion. 2, 3 In theory, any agent that lowers BP should slow the progression of CRF. However, different antihypertensives (AHTs) alter glomerular haemodynamics to different extents. Accumulating data suggest that for any given level of systemic BP reduction, angiotensin converting enzyme inhibitors (ACE-I) produce superior antiproteinuric and renoprotective effects, especially in diabetics and in patients with established proteinuria. 4 In the USA, the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC) has published guidelines for the treatment of hypertension. JNC VI (published in 1997) and the recently published JNC VII recommend that hypertensive patients with CRF should receive, unless contraindicated, an ACE-I. Multidrug regimens will often be necessary, and diuretics are suggested as the second AHT drug. Angiotensin receptor blockers (ARBs) are increasingly seen as alternative AHTs in renal failure. 5, 6 While the efficacy of different AHTs in patients with CRF has been studied in numerous randomised controlled trials, 1 there have been few studies on the effectiveness of these drugs in clinical nephrology practice. Optimal outcome of medical treatment in routine care depends not only on patient compliance with drug regimens, but also on prescriptioner adherence to evidence-base or therapeutic guidelines. JNC VI recommended that CRF patients had their BP controlled to p130/85 mmHg, or p125/ 75 mmHg if proteinuria exceeded 1 g/d. 5 In JNC VII the recommended target BP was changed to o130/ 80 mmHg for all patients with chronic kidney disease defined as GFR less than 60 ml/min per 1.73 m 2 or albuminuria (4300 mg/d or 200 mg albumin per gram of creatinine). 6 It is stated that most patients with hypertension will require two or more AHTs to achieve their target BP.
To assess the impact of the JNC VI guidelines published in 1997, a cross-sectional study of BP control in CRF patients at the beginning of 2001 was performed. Patients who had reached end-stage renal disease (ESRD), that is who were treated with dialysis or kidney transplantation, were not included. The aim of the study was to investigate to what extent and with which AHTs the JNC VI recommendations were achieved for patients treated by nephrologists at the University Hospital of NorthNorway (UNN), as a part of the Section of Nephrology's quality assurance of drug treatment.
Material and methods

Patients
In Norway, health insurance coverage is universal, and people across all income levels use public health services. Their primary care physician or local hospital refers patients to UNN. The hospital is the only provider of nephrological services in the northern part of North-Norway. All patients with pre-ESRD CRF treated at the hospital on 1, January 2001 were identified from the hospital's database of serum creatinine (S-Cr) measurements. In this study, CRF was defined as persisting S-Cr values above the upper limit of the reference interval for at least 1 year, including at least two values higher than 25 % above the upper reference interval at least 1 year apart (men: 4150 mmol/l; women: 4125 mmol/l). Patients whose medical record documented contact with the hospital's section of nephrology were included in the study. Those who had at any time received renal replacement therapy (dialysis or transplant) were excluded.
Data
Each patient's last measured BP before 1, January 2001 was registered. In the nephrology outpatient clinic, BP was measured as the arithmetic mean of the last two of three measurements after 5 min rest in the sitting position. BP measurements were performed by a nurse using an automatic device (Colin Press-Mate BP 8800, Colin Medical Instruments Corp., San Antonio, TX, USA). If the patient's last contact with the hospital was an admission, the last measurement before discharge was used. Data on analyses of urinary protein and creatinine were obtained from the hospital's database of clinical chemical analyses. The protein:creatinine ratio (PC ratio) was calculated when both analyses had been performed on the same sample. Samples where the protein concentration had been measured as less than 0.2 g/l, or where a standard dipstick test had been negative for protein, were classified as having a PC ratio of zero. The patients were grouped in the categories PC ratio p1, 41.0 and ''unknown'' according to their last measured PC ratio before 1, January 2001. The PC ratio has been found to estimate 24 h urinary protein excretion in grams per day reliably. 7 The BP goal was defined in accordance with the JNC VI, as this was the guideline to be considered from 1997 until the time of data sampling. JNC VI target BP is p130/85 mmHg (corresponding to MAP p98) for patients with PC ratio p1, and 125/ 75 mmHg (MAP p92) for patients with PC ratio 41. The goal was assessed as achieved only if both SBP and DBP were sufficiently low. The target BP for patients with unknown PC ratio was set at 130/ 85 mmHg to obtain an upper bound for the degree of goal achievement. All patients' medical records were examined by a nephrologist (BOE), and their CRF aetiology registered. In cases where the aetiology was stated in the medical record, the CRF was classified correspondingly, otherwise it was classified as 'unknown'. The occurrence of diabetes mellitus was registered without distinguishing between type I and type II. All drugs in use at the last contact before 1st January 2001 were registered. In this study, AHTs included a-and b-adrenergic blockers, ACE-I, ARB, calcium channel blockers and diuretics (thiazides, loop diuretics, spironolactone). The study was approved by The Norwegian Data Inspectorate.
Statistical analyses
Statistical associations between MAP, SBP or DBP and other variables were investigated with univariate linear regression analyses. Associations between the number of AHT and other variables were analysed with univariate Poisson regression using SAS (SAS Institute, Cary, NC, USA). The 95% confidence intervals (CI) for proportions were calculated as exact binomial CI.
Results
Patients' characteristics and aetiology
A total of 321 patients with CRF were identified. Of these, 102 received renal replacement therapy, and 75 patients were excluded due to lack of contact with a nephrologist. Thus, a total of 144 patients were included in the study. Patient characteristics are shown in Table 1 . The PC ratio could not be calculated, and was hence classified as unknown, for 34 patients. For 16 of these patients, no information on analysis of urinary protein or dipstick test could be found in the medical record or in the database. The remaining 18 patients all had some degree of proteinuria on one or more occasions, but there were insufficient data to calculate the PC ratio. The underlying cause of the CRF is given in Table 2 .
BP and achievement of BP goals
Failure to control SBP was more common than failure to control DBP. In all, 22% of the patients achieved both the SBP and the DBP goal, while twice as many achieved the corresponding MAP goal. Further data on the extent of BP goal achievement are given in Table 3 .
Univariate linear regression analyses were performed with SBP and DBP as the dependent and one of the following as the independent variable: age, gender, S-Cr, PC ratio and diabetes mellitus (yes/no). The only statistically significant association found was a higher SBP with increasing age (P ¼ 0.005). The same analyses were performed with MAP as the dependent variable. No statistically significant associations were found, but there was a tendency for increasing MAP with increasing PC ratio (P ¼ 0.07) for the patients in whom it had been measured. Table 4 shows the prescription frequency of different AHT drug classes. Drugs targeting the renin-angiotensin system were the most frequently prescribed AHT, as a total of 79 patients (55%) had an ACE-I or ARB in their drug regimen. JNC VI recommended that a combination of ACE-I and loop diuretic was a part of the drug regimen for 33 (23%) of the patients. ACE-I (n ¼ 17) or ARB (n ¼ 3) was a part of the antihypertensive regimen for 20 of the 27 patients (74%) with diabetes. Of the 36 patients with PC ratio 41, 28 (78%) were prescribed ACE-I (n ¼ 24) or ARB (n ¼ 4). The most frequently prescribed drug substance with antihypertensive effect was frusemide (n ¼ 73, or 51%). Diuretics (frusemide, thiazides, spironolactone) were prescribed in 89 (62%) of the cases.
Antihypertensive medication
Failure to achieve target BP was observed among patients prescribed a varying number of AHTs as well as among patients not prescribed such medication at all (Table 5) , although no causal relation between BP and number of AHTs could be confirmed. The mean number of AHTs prescribed per patient was 2.0, varying from 0 to 6. Univariate Poisson regression analyses were performed with the number of AHTs prescribed as the dependent variable and one of the following as the independent variable: age, gender, PC ratio, S-Cr, MAP, SBP, DBP and diabetes. Diabetic patients were prescribed a significantly higher number of AHTs than nondiabetics (2.5 as compared to 1.9, P ¼ 0.03). No other statistically significant associations were found.
We observed as many as 17 different combinations of drug classes among 40 patients prescribed two AHTs. The most frequently observed two-drug Blood pressure control in chronic renal failure T Giverhaug et al regimen was b-blocker and loop diuretic (eight cases). Six (15%) of the 40 patients on two AHTs were prescribed ACE-I and loop diuretic. Most of the patients were prescribed drugs in addition to AHTs, and the mean total number of drugs prescribed for a patient was 5.8 (s.d. 2.8). Polypharmacy was common, although the number of drugs actually used by each patient could not be calculated since neither the patients' compliance with the drug regimen nor their use of prescriptionfree drugs were registered.
Discussion
BP and goal achievement
In this study, we identified all pre-ESRD CRF patients treated by nephrologists in the only hospital providing nephrological services to a welldefined geographical area. Only 22% of the patients achieved the JNC VI recommended SBP/DBP. Since the goal for patients with unknown PC ratio was set at 130/85 mmHg, this estimate represents an upper bound for the actual goal achievement.
Search in MedLine and EMBase only revealed three studies [8] [9] [10] on the effectiveness of antihypertensive treatment in CRF in nephrological practice published after the JNC VI report in 1997. Failure to achieve BP goals occurred with a similar frequency as in the current study, but lack of data on urinary protein excretion and different definitions of BP treatment goals in two of the studies 9,10 make comparisons difficult. Tonelli et al 8 reported an overall MAP goal achievement of 42%, as compared to 44% in the present study. Mean achieved SBP/ DBP and MAP were similar in all the effectiveness studies including the present one (range SBP 140-147 mmHg, DBP 78-85 mmHg, MAP 99-103 mmHg). Failure to control SBP was not reported separately in the other studies but occurred in 74% of our patients. SBP has been identified as a stronger predictor of GFR decline than DBP 5 , and the issue of to what extent the recommended level can be achieved is important.
In the MDRD study, the mean achieved MAP in patients with proteinuria less than and greater than 1 g/d was 96.5 and 100.1 mmHg, respectively, that is lower than in the effectiveness studies. 11 However, patients with high values of MAP, proteinuria or SCr were excluded from the MDRD study, which may explain the difference. In the recently published African American Study of Kidney Disease and Hypertension (AASK) 12 the degree of BP goal achievement was considerably higher than in the Blood pressure control in chronic renal failure T Giverhaug et al present study. However, the included patients were younger, healthier and probably more adherent to their drug therapy than ours, as only self-identified patients with impaired renal function due to essential hypertension were included. Approximately 60% of hypertensive patients with renal failure randomised to the low goal (MAP p92 mmHg) and 80% randomised to the usual goal (MAP 102-107 mmHg) had MAP values at or below the goal at 32 months of follow-up in the AASK study. Thus, the MDRD and the AASK studies both document BP treatment success, but in rather selected patient populations. Prospective studies with optimal treatment and follow-up of patients in clinical practice are needed to clarify to what extent goal achievement can be expected in more heterogeneous populations. The results of such studies should be given in terms of SBP/DBP instead of MAP, to prevent undertreatment of patients with systolic hypertension despite MAP at or below target. Although JNC has defined upper limits for BP in patients with CRF, the optimal BP for preserving renal function remains to be defined. Aggressive lowering of BP can give rise to unacceptable side effects especially in older patients, and this may be one of the factors limiting antihypertensive treatment in clinical practice. Similarly, clinical inertia, or health-care providers' failure to initiate or intensify antihypertensive treatment, has been noted as a prominent problem. 13 Audit of clinical practice against a guideline can be a means of overcoming this.
Antihypertensive medication and prescription patterns
In all, 55% of the patients in the current study were prescribed ACE-I or ARB and were thus treated according to the JNC recommendations. In two of the other effectiveness studies, the prescription frequency of ACE-I/ARB was 64% 8 and 27-38% depending on the degree of proteinuria. 10 It was beyond the scope of the present study to find out why ACE-I or ARB were not prescribed for individual patients, but it is unlikely that every second patient had contraindications against such drugs. Tonelli et al 8 suggested that the maximum achievable use of ACE-I might be as high as 90%, which is why we assume that there was a potential for increased prescription of ACE-I or ARB in our hospital. Particularly, hypertensive CRF patients not prescribed AHT at all, and patients prescribed one or two AHT, would probably have benefited from having ACE-I or ARB added to their drug regimen. Patients on multi-drug AHT regimens not including ACE-I or ARB should be considered for such drugs, either in addition to or in place of second-or third-line AHTs. The variety observed in the composition of two-drug AHT regimens indicates a need for standardisation of prescription relative to evidence-base. However, the higher prescription frequency of ACE-I/ARB observed in groups of patients at high risk of progression to ESRD (higher proteinuria or diabetes) may indicate an increasing awareness of the superiority of these drugs to other AHTs in CRF.
The mean number of AHT prescribed in our study (2.0) was similar to that reported by Tonelli et al (2.2), 8 but lower than in the AASK study demonstrating successful BP control in hypertensive African Americans with CRF (3.0). 12 However, a comparison of the number of drugs required is of limited value without ensuring that optimal dose titration has been performed and that comorbidity has been taken into account. In the AASK study, 12 the dosage of each AHT was titrated to the maximum tolerated dose before adding a new agent. In the present study, some of the patients suffered from heart diseases and were probably prescribed drugs here defined as AHT for indications other than hypertension. Since the optimal dosage of a certain drug may change over time according to changes in renal function and co-morbidity, it is important to ensure good routines for regular re-evaluation and optimisation of drug therapy.
Failure to achieve the treatment goal is often ascribed to patient nonadherence. It is generally thought that at least 30% of prescribed drugs are not taken as directed, and that non-adherence is an important barrier to achieving the best results from medication.
14 The high total number of drugs prescribed to many patients in the current study was probably not compatible with high adherence, although this was not investigated. However, the assumption that high adherence is good for the patient will only be true if the prescription represents the best treatment option for the individual patient. Prescriptioners' adherence to evidence-base must therefore be ensured. JNC VII suggests different decision support systems and involvement of nurse clinicians and pharmacists to overcome a clinician's failure to titrate or combine medications despite knowing the patient is not at goal BP. 6 
Limitations
The low number of patients included in this study (n ¼ 144) limits its power for detecting differences between subgroups. On the other hand, access to a complete database of S-Cr measurements made it possible to identify all CRF patients by the nephrologist at our hospital. Since UNN is the only hospital providing nephrological services in the northernmost part of North-Norway, no bias was caused by selective referral of patients to our hospital. The number of included patients is sufficient to draw conclusions about the quality of BP control, as none of the upper limits of the 95% CI can be considered satisfactory according to the recommendations in JNC VI.
The percentage of patients with diabetic nephropathy included in the present study (9%) was low, but consistent with the lower incidence of diabetic nephropathy in Norway than in the US and continental Europe. According to the Norwegian Renal Registry, 11% of new cases of ESRD were caused by diabetic nephropathy in the period 1995-1999. 15 Due to unknown PC ratio for a high proportion of the patients, the low degree of BP goal achievement in the present study is probably nonetheless too optimistic. This strengthens the conclusion that the recommended BP is difficult to achieve in clinical practice. The fact that no information on proteinuria could be found in the medical records of a considerable number of patients indicates a need for better routines at the nephrology unit.
We conclude that the BP goal recommended by JNC may be difficult to achieve in a high proportion of patients in clinical practice. While DBP was fairly well controlled in most patients in the current study, goal achievement was prevented by high SBP. There is a potential for improved treatment of hypertension in CRF, including increased prescription of ACE-I and ARB. Future strategies for improved BP control in CRF in our hospital include implementation of written guidelines for the prescription of antihypertensive therapy, regular re-evaluation of a patient's total drug regimens, and increased focus on a patient's adherence to drug therapy.
